Clinical development of the novel oncolytic coxsackievirus B3 targeting malignant tumors
Project/Area Number |
23240133
|
Research Category |
Grant-in-Aid for Scientific Research (A)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Clinical oncology
|
Research Institution | Kyushu University |
Principal Investigator |
TANI Kenzaburo 九州大学, 生体防御医学研究所, 教授 (00183864)
|
Co-Investigator(Renkei-kenkyūsha) |
SHIMIZU Hiroyuki 国立感染症研究所, ウイルス第2部, 室長 (90270644)
|
Project Period (FY) |
2011-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥49,140,000 (Direct Cost: ¥37,800,000、Indirect Cost: ¥11,340,000)
Fiscal Year 2013: ¥11,440,000 (Direct Cost: ¥8,800,000、Indirect Cost: ¥2,640,000)
Fiscal Year 2012: ¥13,260,000 (Direct Cost: ¥10,200,000、Indirect Cost: ¥3,060,000)
Fiscal Year 2011: ¥24,440,000 (Direct Cost: ¥18,800,000、Indirect Cost: ¥5,640,000)
|
Keywords | 腫瘍溶解性ウイルス / コクサッキーウイルスB群3型 / miRNA / 顆粒球マクロファージ刺激因子 / ウイルス製剤製造 / 一般毒性試験 / GM-CSF / 腫瘍溶解ウイルス / 医薬品医療機器総合機構 / 一般毒性試 / GMP準拠 / 担癌マウスモデル / ウイルス製造 / 腫瘍溶解性ウイルス療法 / コクサッキーウイルス / GMP / 顆粒球マクロファージコロニー刺激因子 / microRNA / コクサッキーウイルス(CV)B3 / 密度勾配遠心法 / miRNA相補配列挿入CVB3 / 遺伝子改変CVB3 / miR-1 / miR-217 / CVB3精製 |
Outline of Final Research Achievements |
Oncolytic viruses are characterized by self-replicating and tumor killing capacity, and have emerged as a promising treatment platform for cancer therapy. We previously carried out the screening of approximately 40 enterovirus strains and found that CVB3 possessed specific oncolytic activity against cell lines of human lung cancer, malignant pleural mesothelioma and breast cancer. In this study, two experiments were performed for the development of the novel oncolytic coxsackievirus B3 therapy. (1) To overcome CVB3-related organ toxicities, we constructed a novel recombinant CVB3-miRT by genetically incorporating two distinct normal tissue-specific miRNA target sequences into the CVB3 genome. We next constructed CVB3 inserting GM-CSF gene (CVB3-GM-CSF) to improve anti-tumor immunity. (2) For the purpose of producing CVB3 reagent under Good Manufacturing Practice (GMP), we developed mass production method using GMP grade reagents and instruments.
|
Report
(4 results)
Research Products
(27 results)
-
-
[Journal Article] Inhibition of PTEN tumor suppressor promotes the generation of induced pluripotent stem cells.2013
Author(s)
Liao J, Marumoto T, Yamaguchi S, Okano S, Takeda N, Sakamoto C, Kawano H, Nii T, Miyamoto S, Nagai Y, Okada M, Inoue H, Kawahara K, Suzuki A, Miura Y and Tani K
-
Journal Title
Molecular Therapy
Volume: in press
Issue: 6
Pages: 1242-1250
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] 肺癌幹細胞を標的とした新規遺伝子改変麻疹腫瘍溶解性ウイルス療法2013
Author(s)
Hiroyuki Inoue, Keisuke Yasunari, Yumiko Matsumura, Kaname Nosaki, Shohei Miyamoto, Koichi Takayama, Yoichi Nakanishi, and Kenzaburo Tani
Organizer
第53回日本呼吸器学会学術講演会
Place of Presentation
東京
Year and Date
2013-04-19
Related Report
-
-
-
-
-
-
-
-